An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant
Latest Information Update: 30 Aug 2023
At a glance
- Drugs Patisiran (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
Most Recent Events
- 28 Aug 2023 Results published in the Clinical Pharmacokinetics
- 25 Feb 2022 Results published in the American Journal of Transplantation
- 07 Jun 2021 According to an Alnylam Pharmaceuticals media release, results from this study were presented at the 2021 Peripheral Nerve Society Annual Meeting.